Literature DB >> 19646346

Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis.

J D Finkielman1, P A Merkel, D Schroeder, G S Hoffman, R Spiera, E W St Clair, J C Davis, W J McCune, A Lears, S R Ytterberg, A M Hummel, M A Viss, T Peikert, J H Stone, U Specks.   

Abstract

OBJECTIVE: The glycosylation status of autoantigens appears to be crucial for the pathogenesis of some autoimmune diseases, since carbohydrates play a crucial role in the distinction of self from non-self. Proteinase 3 (PR3), the main target antigen for anti-neutrophil cytoplasmic antibodies (ANCA) in patients with Wegener's granulomatosis (WG), contains two Asn-linked glycosylation sites. The present study explores the influence of the glycosylation status of PR3 on the PR3 recognition by ANCA in a well characterized population of patients with WG.
METHODS: Forty-four patients with WG (459 serum samples) who participated in a multicenter randomized trial, were tested by capture ELISA for ANCA against PR3 and deglycosylated recombinant variants of PR3.
RESULTS: The patients were followed for a median of 27 months, and the median number of serum samples per patient was 10. At baseline, the correlation between the levels of ANCA against PR3 and against all the deglycosylated recombinant variants of PR3 were greater than 0.94 (?<0.001 for all the comparisons). Longitudinal analyses comparing the levels of ANCA against PR3 versus all the deglycosylated recombinant variants of PR3, using linear mixed models, showed no significant statistical differences (rho >or=0.90 in all cases).
CONCLUSION: The glycosylation status of PR3 has no impact on its recognition by ANCA in WG.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19646346      PMCID: PMC3183098     

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  27 in total

1.  Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity.

Authors:  L Casciola-Rosen; F Andrade; D Ulanet; W B Wong; A Rosen
Journal:  J Exp Med       Date:  1999-09-20       Impact factor: 14.307

2.  Cloning and functional expression of the murine homologue of proteinase 3: implications for the design of murine models of vasculitis.

Authors:  D E Jenne; L Fröhlich; A M Hummel; U Specks
Journal:  FEBS Lett       Date:  1997-05-19       Impact factor: 4.124

3.  Requirement of glycosylation of the human thyrotropin receptor ectodomain for its reactivity with autoantibodies in patients' sera.

Authors:  G S Seetharamaiah; J S Dallas; S A Patibandla; N R Thotakura; B S Prabhakar
Journal:  J Immunol       Date:  1997-03-15       Impact factor: 5.422

4.  The crystal structure of PR3, a neutrophil serine proteinase antigen of Wegener's granulomatosis antibodies.

Authors:  M Fujinaga; M M Chernaia; R Halenbeck; K Koths; M N James
Journal:  J Mol Biol       Date:  1996-08-16       Impact factor: 5.469

5.  A proportion of proteinase 3 (PR3)-specific anti-neutrophil cytoplasmic antibodies (ANCA) only react with PR3 after cleavage of its N-terminal activation dipeptide.

Authors:  J Sun; D N Fass; M A Viss; A M Hummel; H Tang; H A Homburger; U Specks
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

6.  The p68 autoantigen characteristic of rheumatoid arthritis is reactive with carbohydrate epitope specific autoantibodies.

Authors:  S Bläss; C Meier; H W Vohr; M Schwochau; C Specker; G R Burmester
Journal:  Ann Rheum Dis       Date:  1998-04       Impact factor: 19.103

7.  Autoantibodies to the protein core of vascular basement membrane heparan sulfate proteoglycan in systemic lupus erythematosus.

Authors:  H Fillit; S Shibata; T Sasaki; H Spiera; L D Kerr; M Blake
Journal:  Autoimmunity       Date:  1993       Impact factor: 2.815

8.  Capture-ELISA based on recombinant PR3 is sensitive for PR3-ANCA testing and allows detection of PR3 and PR3-ANCA/PR3 immunecomplexes.

Authors:  J Sun; D N Fass; J A Hudson; M A Viss; J Wieslander; H A Homburger; U Specks
Journal:  J Immunol Methods       Date:  1998-02-01       Impact factor: 2.303

9.  Wegener granulomatosis: an analysis of 158 patients.

Authors:  G S Hoffman; G S Kerr; R Y Leavitt; C W Hallahan; R S Lebovics; W D Travis; M Rottem; A S Fauci
Journal:  Ann Intern Med       Date:  1992-03-15       Impact factor: 25.391

10.  Characterization of a recombinant proteinase 3, the autoantigen in Wegener's granulomatosis and its reactivity with anti-neutrophil cytoplasmic autoantibodies.

Authors:  V Witko-Sarsat; L Halbwachs-Mecarelli; R P Almeida; P Nusbaum; M Melchior; G Jamaleddine; P Lesavre; B Descamps-Latscha; J E Gabay
Journal:  FEBS Lett       Date:  1996-03-11       Impact factor: 4.124

View more
  3 in total

1.  Discrimination and variable impact of ANCA binding to different surface epitopes on proteinase 3, the Wegener's autoantigen.

Authors:  Francisco Silva; Amber M Hummel; Dieter E Jenne; Ulrich Specks
Journal:  J Autoimmun       Date:  2010-12       Impact factor: 7.094

2.  Interventions for renal vasculitis in adults.

Authors:  Giles D Walters; Narelle S Willis; Tess E Cooper; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2020-01-13

Review 3.  Pathogenicity of Proteinase 3-Anti-Neutrophil Cytoplasmic Antibody in Granulomatosis With Polyangiitis: Implications as Biomarker and Future Therapies.

Authors:  Jérôme Granel; Brice Korkmaz; Dalila Nouar; Stefanie A I Weiss; Dieter E Jenne; Roxane Lemoine; Cyrille Hoarau
Journal:  Front Immunol       Date:  2021-02-18       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.